| Document and Entity Information | Nov. 07, 2023 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001723128 |
| Document Type | 8-K/A |
| Document Period End Date | Nov. 07, 2023 |
| Entity Registrant Name | AMNEAL PHARMACEUTICALS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38485 |
| Entity Tax Identification Number | 93-4225266 |
| Entity Address, Address Line One | 400 Crossing Blvd |
| Entity Address, City or Town | Bridgewater |
| Entity Address, State or Province | NJ |
| Entity Address, Postal Zip Code | 08807 |
| City Area Code | (908) |
| Local Phone Number | 947-3120 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Class A Common Stock, par value $0.01 per share |
| Trading Symbol | AMRX |
| Security Exchange Name | NYSE |
| Entity Emerging Growth Company | false |
| Amendment Description | This Form 8-K/A is filed as an amendment to the Current Report on Form 8-K filed by Amneal Pharmaceuticals, Inc. on November 8, 2023 (the “Original Form 8-K”) solely in order to file a corrected Exhibit 3.2 to the Original Form 8-K (which supersedes and replaces in its entirety Exhibit 3.2 to the Original Form 8-K). Other than such correction, there are no other changes to the Original Form 8-K. |
